Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Akebia Therapeutics Inc (NASDAQ:AKBA)

9.94
Delayed Data
As of Feb 24
 +0.01 / +0.10%
Today’s Change
7.00
Today|||52-Week Range
11.07
-4.51%
Year-to-Date
3 Biotech Stocks You May Be Overlooking
Feb 22 / MotleyFool.com - Paid Partner Content
Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb 13 / Zacks.com - Paid Partner Content
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%
Feb 15 / Zacks.com - Paid Partner Content
Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
Feb 13 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exeli...
Feb 14 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close9.93
Today’s open9.85
Day’s range9.78 - 9.98
Volume130,424
Average volume (3 months)220,038
Market cap$380.6M
Dividend yield--
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)+71.52%
Earnings growth (this year)-61.30%
Earnings growth (next 5 years)+15.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book2.32

Competitors

 Today’s
change
Today’s
% change
ADMSAdamas Pharmaceutica...-0.05-0.29%
MYOKMyoKardia Inc+0.20+1.67%
TLGTTeligent Inc+0.14+1.93%
OBSVObseva SA+0.74+5.58%
Data as of 4:00pm ET, 02/24/2017

Financials

Next reporting dateMarch 8, 2017
EPS forecast (this quarter)-$1.09
Annual revenue (last year)$0.00
Annual profit (last year)-$60.7M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO &
Class III Director
John P. Butler
CFO, Treasure, SVP &
Principal Accounting Officer
Jason A. Amello
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs